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ABSTRACT 
Background: Type 2 Diabetes mellitus is a multisystem disorder with oxidative stress 
and endothelial dysfunction. Withania somnifera Dunal (Ashwagandha) is shown to 
have potent antioxidant, hypoglycemic and hypolipidemic effects in several studies. 
The present study was planned to compare the effect of Withania somnifera on 
endothelial dysfunction and biomarkers in patients with diabetes mellitus. Materials 
and Methods: After taking IEC approval and written informed consent, 66 eligible 
patients, who are on metformin therapy, were randomized to receive either one 
capsule of highly standardized aqueous extract of Withania somnifera 250mg twice 
daily, one capsule of Withania somnifera 500mg twice daily or Placebo for a duration of 
12 weeks. Primary efficacy parameter was a change in endothelial function (measured 
as change in reflection index of more than 6 %) performed by salbutamol challenge test 
at baseline and after 12 weeks of treatment. Secondary end points were change in 
biomarkers of oxidative stress (malondialdehyde, nitric oxide and glutathione), high 
sensitivity C-reactive protein and change in lipid profile. Safety lab parameters were 
measured, at baseline and after 12 weeks of treatment. Results: A total of 60 patients 
completed the study. Twelve weeks of treatment with Withania somnifera 250mg and 
500mg produced significant reduction in reflection index (-2.52±1.32% to -
7.49±3.49%) and (-2.24±1.00% to -9.03± 2.42%) respectively, suggesting 
improvement in endothelial function versus placebo (-2.11±1.62% to -0.81± 2.86%). 
Similarly a significant improvement in biomarkers of oxidative stress, systemic 
inflammation, lipid parameters and HbA1c levels, compared to baseline and placebo, 
was observed with Withania somnifera. All treatments are well tolerated. Conclusion: 
Withania somnifera showed significant improvement in endothelial function, reduction 
in biomarkers of oxidative stress and systemic inflammation and can be used as a 
therapeutic adjunctive in patients with type 2 Diabetes mellitus. 
KEYWORDS: Withania somnifera, Ashwagandha, Oxidative stress, Endothelial 
dysfunction. 
INTRODUCTION  
Cardiovascular diseases (CVD), 
comprising coronary heart disease (CHD) and 
cerebro-vascular diseases, are the leading cause 
of death globally, accounting for 21.9 per cent of 
total deaths and are projected to increase to 26.3 
per cent by 2030[1]. For India this increase is 
estimated to be 58%, from 51 million people in 
2010 to 87 million in 2030[2]. Among the risk 
factors, diabetes and its predominant form, type 
2 diabetes mellitus (T2DM), has a distinctive 
association with CHD. Atherosclerosis accounts 
for approximately 80% of all diabetic mortality 
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and about 75% of this is a consequence of 
coronary artery disease, the remaining 25% 
results from accelerated cerebrovascular and 
peripheral vascular disease[3]. Endothelial 
dysfunction is believed to be important in the 
pathogenesis of microvascular and 
macrovascular disease especially leading to a 
marked increase in atherosclerotic vascular 
disease[4]. Endothelial dysfunction results from 
reduced bioavailability of the vasodilator nitric 
oxide (NO) mainly due to accelerated NO 
degradation by reactive oxygen species[5]. 
Oxidative stress, through a single unifying 
mechanism of superoxide production, is the 
common pathogenic factor leading to insulin 
resistance, β-cell dysfunction, impaired glucose 
tolerance and ultimately to type 2 DM and has 
been implicated as the underlying cause of both 
the macrovascular and microvascular 
complications associated with it. It follows that 
therapies aimed at reducing oxidative stress 
would benefit patients with type 2 DM and those 
at risk for developing diabetes[6,7]. The spectrum 
of dyslipidemia in diabetes mellitus can include 
all the various types of dyslipidemia identified in 
the general population[8]. Drugs like statins, ACE-
Inhibitors etc have been effectively tried for 
endothelial dysfunction, but are associated with 
side effects. Some herbal formulations are 
reported to possess potent antioxidant, anti-
inflammatory and cardio-protective properties 
and are used by patients with increased risk of 
cardiovascular morbidity and mortality. 
Withania somnifera, also known as 
Ashwagandha is an important herb in the 
Ayurvedic and indigenous medical system. The 
active principles of Withania somnifera 
sitoindosides VII-X and Withaferin A 
(glycowithanolides) have shown to possess 
antioxidant effects. Several studies indicated that 
Withania somnifera has antitumor, antistress, 
anti-inflammatory and rejuvenating 
properties[9].  
The present study was thus undertaken 
to evaluate the effect of highly standardized 
aqueous extracts of Withania somnifera 250mg, 
Withania somnifera 500mg and Placebo on 
endothelial function in patients with type 2 
diabetes mellitus and further study its probable 
mechanism of action.  
 
 
MATERIALS AND METHODS 
The present study was a randomized, 
double blind, placebo controlled, parallel design 
conducted in the Department of Clinical 
Pharmacology and Therapeutics, Nizam’s 
Institute of Medical Sciences, Hyderabad, India. 
Sixty six patients were enrolled in the study 
which was approved by the Institutional Ethics 
Committee. All subjects gave written Informed 
consent prior to participation in the study. 
Patients of either gender, aged 18-65 years, 
fasting plasma glucose between 110 -126 mg/dL, 
a glycosylated hemoglobin (HbA1c) between 6.5 
% and 8% and taking stable dose of anti-diabetic 
treatment (Metformin 1500-2500 mg/day[10]) 
for the past 8 weeks prior to the screening visit; 
and having endothelial dysfunction defined as ≤ 
6% change in reflection index (RI) on post 
salbutamol challenge test were included in the 
study. Patients with severe uncontrolled 
hyperglycemia, uncontrolled hypertension, 
cardiac arrhythmia, impaired hepatic or renal 
function, history of malignancy or stroke, 
smoking, chronic alcoholism, any other serious 
disease requiring active treatment and 
treatment with any other herbal supplements, 
were excluded from the study.  
Study Medication 
In the present study we used SENSORIL® 
an aqueous extract of the roots of Withania 
somnifera (Ashwagandha) and is highly 
standardized by HPLC as shown in Fig. 1, 
containing not less than 10% withanolide 
glycosides, not more than 0.5% of Withaferin-A 
and not less than 32% of oligosaccharides in the 
dose of 250mg twice daily and 500mg twice 
daily. Identical matching placebo capsules were 
used. 
Estimation of Withanolide glycosides, 
aglycones and Oligosaccharides in Withania 
somnifera extracts (Sensoril®) 
Withania somnifera extract (roots), used 
in this study, was standardized to contain 
withanolide glycosides (not less than 10% w/w), 
Oligosaccharides (not less than 32% w/w) and 
aglycones (Withaferin-A) (not more than 0.5% 
w/w) by HPLC using external standards 
(isolated from Withania somnifera root extract 
by column chromatography). Briefly, Withania 
somnifera extract (200 mg) was dissolved in 
distilled water (20 ml), sonicated for 10 min and 
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heated on steam bath for 10 min followed by 
centrifugation at 8500 rpm for 12 min. The 
water soluble portion (supernatant) was diluted 
with millipore water to get 2.5 mg/ml for 
Withanolide glycosides and aglycones 
quantification, whereas 10mg/ml was used for 
oligosaccharide quantification. This solution was 
filtered through 0.2 µm syringe filter and 20µl 
was used for HPLC analysis using the following 
conditions. 
(i). Withanolide glycoside and aglycones 
estimation: Waters HPLC system (equipped 
with 515 model pump, Waters TM 2996 
photodiode array detector and empower 
software); the column used was Lichrocart 
RP C18 250X4 mm 5µm (Merck; LO 
10138433) using Acetonitrile:Water (1:1) 
as mobile phase at a flow rate of 0.6 ml/min 
and detection wavelength 225 nm. The 
percentage content of Withanolide 
glycosides and aglycones were calculated 
using area of the respective peaks and the 
linear regression equation (y = 3000006x + 
45860) of the external standard.  
(ii). Oligosaccharide estimation: Waters HPLC 
system (equipped with 515 model pump, 
Waters TM 2414 Refractive Index detector 
and empower software); the column used 
was Carbohydrate analysis 300X3.9 mm 
(Waters: WAT 084038) column using 
Acetonitrile:Water (80:20) as mobile phase 
at a flow rate of 2 ml/min. The percentage 
content of Oligosaccharides were calculated 
using area of the oligosaccharide peaks and 
the linear regression equation (y = 
10142x+51551) of the external standard. 
Methodology 
After screening, all the eligible subjects 
were randomized to receive either one of the 
three treatments, one capsule of W.somnifera 
250mg twice daily or W.somnifera 500mg twice 
daily or Placebo twice daily for 12 weeks. 
Subjects were reviewed for follow up at 4, 8 and 
12 weeks of therapy. At each visit they were 
evaluated for efficacy and safety. 
Pharmacodynamic evaluation for endothelial 
function was conducted before and at the end of 
the treatment. Blood samples were collected for 
evaluation of biomarkers at baseline and end of 
treatment. Similarly safety lab investigations for 
hematological, hepatic and renal biochemical 
parameters were conducted before and at the 
end of the study and also as and when required 
in case of any adverse drug reaction (ADR). 
Subjects were enquired for the presence of ADR 
and the same was recorded in the case report 
form. Compliance to therapy was assessed by pill 
count method. 
Primary and Secondary Efficacy Parameters 
The primary efficacy measure was a 
change in endothelial dysfunction as assessed by 
more than 6% change in reflection index at 12 
weeks in all the treatment groups. Secondary 
efficacy parameters include change in oxidative 
stress markers, Serum levels of nitric oxide, 
hsCRP (high sensitivity C-reactive protein) and 
lipid profile at 12 weeks in all the treatment 
groups. Additionally, safety and tolerability 
assessment of the test medications were also 
conducted. 
Assessment of Endothelial Function 
A salbutamol challenge test employing 
digital volume plethysmography was used to 
assess endothelial function as reported by 
Chowienezyk et al[11] and Naidu et al [12]. Patients 
were examined in supine position after 5 
minutes of rest. A digital volume pulse (DVP) 
was obtained using photo plethysmograph 
(Pulse Trace PCA2, PT200, Micro Medical, Kent, 
UK) transmitting infrared light at 940 nm, placed 
on the index finger of right hand. The signal from 
the plethysmograph was digitized using a 12 bit 
analogue to digital converter with a sampling 
frequency of 100 Hz. DVP waveforms were 
recorded over 20 second period and the height 
of the late systolic / early diastolic portion of the 
DVP was expressed as a percentage of the 
amplitude of the DVP to yield the reflection 
index (RI), as per the procedure described in 
detail by Millaesseau et al [13]. After DVP 
recordings had been taken, three measurements 
of reflection index (RI) were calculated and the 
mean value was determined. Patients were then 
administered 400µg of salbutamol by inhalation. 
After 15 minutes three measurements of RI were 
obtained again and the difference in mean RI 
before and after administration of salbutamol 
was used for assessing endothelial function. A 
change of ≤6% in RI post salbutamol was 
considered as endothelial dysfunction. 
Evaluation of Biomarkers and Safety 
Parameters  
The levels of Nitric oxide [14], MDA [15], 
Glutathione[16] were estimated 
spectrophotometrically and hsCRP (high 
sensitivity C-reactive protein) by ELISA method. 
Samples were collected after an overnight fast 
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for determination of hemoglobin, blood urea and 
serum creatinine, liver function test, lipid profile 
[Total cholesterol, High density lipoprotein 
cholesterol (HDL-C), low density lipoprotein 
cholesterol (LDL-C), very low density lipoprotein 
(VLDL-C) and Triglycerides] using appropriate 
standard techniques. 
Data Analysis 
The data are expressed as mean ± 
standard deviation. ANOVA and Paired t- test 
were used for analysis. A p-value < 0.05 was 
considered to be statistically significant. All 
statistical analyses were performed using the 
Graph pad prism version 4 (Graph pad Software, 
La Jolla, CA, USA).  
RESULTS 
A total of 66 subjects were screened out 
of which 4 patients were excluded because of 
abnormal lab investigation, 2 patients relocated, 
hence unable to continue the study and 60 
subjects completed the study. Twenty subjects 
each in W.somnifera 250mg, W.somnifera 500mg 
and Placebo group completed the study. There 
was no significant difference between treatment 
groups in baseline demographic characteristics 
and the sample was homogenous as shown in 
Table 1. 
Table1: Demographic characteristics of all study groups (All Values expressed as Mean ± SD) 
Parameter W.somnifera 250mg W.somnifera 500mg Placebo 
Total No 20 20 20 
Age in Yrs 55.40±8.07 57.30±9.40 57.45±8.85 
Gender (M/F) 14/6 13/7 12/8 
Bodyweight (Kg) 68.07±6.51 67.30±6.16 66.09±5.56 
BMI (Kg/m2) 24.89±2.03 25.01±2.92 24.82±1.86 
As shown in Table 2 and Fig. 2, at baseline, there was no significant difference of mean 
absolute change in RI between all the three treatments. Treatment with W.somnifera 250 mg and 
W.somnifera 500mg produced significant change in RI compared to baseline and placebo (p<0.001). 
Though there was an apparent better response with 500mg compared to 250mg, the difference was 
however not statistically significant. 
Table 2: Effect of W.somnifera 250, W.somnifera 500mg and Placebo on RI after 12 weeks of 
treatment (All Values expressed as Mean ± SD) 
Notes: *p<0.001 compared to baseline & placebo (F), NS –D and B, F and E 
Nitric oxide, Malondialdehyde, and Glutathione 
levels were used to assess oxidative stress. As 
shown in Table 3, Treatment with W.somnifera 
250 mg and 500 mg significantly reduced 
malondialdehyde levels and increased nitric 
oxide and glutathione levels, suggesting 
improvement in antioxidant status and 
significant reduction in the levels of systemic 
inflammatory biomarker, highly sensitivity C-
reactive protein, after 12 weeks of treatment 
when compared to baseline and placebo. 
W.somnifera 250mg and 500mg showed 
significant increase in NO (p<0.05, p<0.001), GSH 
(p<0.05, p<0.001) and a significant decrease in 
MDA (p<0.05, p<0.001) respectively compared 
to baseline. W.somnifera 500 mg showed a 
significant decrease in MDA (p<0.05) and a 
significant increase in NO (P<0.05), GSH 
(p<0.01) in comparison to W.somnifera 250 mg. 
There was a significant decrease in hsCRP for 
both active treatment groups (p<0.001) as 
compared to baseline and placebo and between 
W.somnifera 250 mg, 500 mg (p<0.05). 
 
 
Parameter W.somnifera 250mg (n=20) W.somnifera 500mg (n=20) Placebo (n=20) 
RI% Pre 
Treatment 
(A) 
Post 
Treatment 
(B) 
Pre 
Treatment 
(C) 
Post 
Treatment 
(D) 
Pre 
Treatment 
(E) 
Post 
Treatment 
(F) 
Mean -2.52 -7.49 * -2.24 -9.03* -2.11 -0.81 
SD ±1.32 ±3.49 ±1.00 ±2.42 ±1.62 ±2.86 
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Table 3: Effect of W. Somnifera 250 mg, W. Somnifera 500 mg and Placebo on Biomarkers of 
oxidative stress after 12 weeks of treatment (All Values expressed as Mean ± SD) 
 Parameter W.somnifera 250 mg 
 (n=20) 
W.somnifera 500mg  
(n=20) 
Placebo 
(n=20) 
 Pre treatment 
(A) 
Post 
treatment 
(B) 
Pre 
treatment 
(C) 
Post 
treatment 
(D) 
Pre 
treatment 
(E) 
Post 
treatment 
(F) 
NO 
(µM/L) 
32.23±20.37 34.60±18.07  29.57±5.94 39.21±10.07  32.62±12.75 31.17±12.62 
MDA 
(nM/ml) 
3.60±1.00 3.26±0.73  3.47±0.99 2.64±0.85  3.58±0.57 3.62±0.51 
GSH 
(µM/L) 
423.85±221.72 474±226.24  404.00±67.37 527.58±103.
84  
420.31±138.97 419.47±134.93 
hsCRP 
(mg/L) 
2.31±0.76 1.38±0.75  2.82±1.27 0.97±0.25  2.27±0.99 2.25±1.04 
Notes: 
NO, p<0.05 for B versus A and D versus B, p<0.001 for D versus C and NS for F versus E 
MDA, p<0.05 for B versus A and D versus B, p<0.001 for D versus C and NS for F versus E 
GSH, p<0.05 for B versus A and p<0.01 for D versus B, p<0.001 for D versus C and NS for F 
versus E 
hsCRP, p<0.001 for B versus A and D versus C, p<0.05 for D versus B, NS for F versus E  
The mean percentage increase in nitric 
oxide for W.somnifera 250 mg and 500mg was 
15.29 % and 33.75% respectively when 
compared to baseline. Both treatments were 
found to be significant when compared to 
placebo as shown in Figure 3. The mean 
percentage decrease in malondialdehyde for 
W.somnifera 250 mg and 500mg was 6.36 %, 
21.39 % respectively when compared to 
baseline. There was a significant decrease for 
W.somnifera 500 mg when compared to placebo 
as shown in Fig. 3.  
The mean percentage increase in 
glutathione for W.somnifera 250 mg and 500mg 
was 14.72%, 31.48 % respectively when 
compared with baseline. Both treatments were 
found to be significant when compared to 
placebo as shown in Figure 4. W.somnifera 250 
mg and 500 mg produced a mean percentage 
decrease of 41.22 % and 57.71 % respectively, 
for high sensitivity C-reactive protein compared 
with baseline. Both treatments were found to be 
significant when compared to placebo as shown 
in Fig. 4 
 In the present study, W.somnifera 
demonstrated lipid lowering effect in patients 
with type 2 diabetes. The results of lipid profile 
are shown in Table 4. 
Table 4: Effect of W.somnifera 250 mg, W.somnifera 500 mg and Placebo on lipid profile after 
12 weeks of treatment (All values expressed as Mean ± SD) 
Parameter W.somnifera 250mg (n=20) W.somnifera 500mg (n=20) Placebo (n=20) 
Pre 
treatment 
Post 
treatment 
Pre 
treatment 
Post 
treatment 
Pre 
treatment 
Post 
treatment 
Total 
Cholesterol 
TC (mg/dl) 
174.9±32.97 160.3±33.32 $ 186.8±19.31 158.0± 15.91 $* 177.2 ±22.73 190.3±22.47 
HDL-C(mg/dl) 40.1± 5.08 40.5± 4.45 NS 40.20±7.46 45.3±5.44 $@ 37.9±5.44 37.4±5.90 
LDL-C(mg/dl) 126.75±40.81 109.7±28.84 # 118.9±16.50 96.25±21.13 $ 125.3±38.79 136.05±44.16 
Triglycerides 
(mg/dl) 
170.2±42.28 147.4±38.59 # 171.9±60.12 131.8± 40.24 $ 166.5±16.62 170.3±17.09 
VLDL-
C(mg/dl) 
32.45±7.27  31.20±7.62 NS 31.55±11.79 28.5±8.68 NS 29.25±6.70 29.0±7.19 
Notes: 
# p<0.01 compared to baseline, placebo, $ p<0.001 compared to baseline, placebo,  
* p<0.05 compared to W.somnifera 500mg vs. 250mg, @ p<0.01compared to W.somnifera 500mg vs. 
250mg, NS- compared to baseline, placebo. In placebo group NS for all parameters compared to 
baseline.  
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 Treatment significantly reduced the 
levels of total cholesterol, low density 
lipoprotein cholesterol and Triglycerides as 
compared to the baseline for W.somnifera 250 
mg (p<0.01) and W.somnifera 500 mg 
(p<0.001). However no significant change was 
found in very low density lipoprotein 
cholesterol levels compared to baseline in both 
active treatment groups. Treatment with 
W.somnifera 500mg showed significant increase 
in high density lipoprotein cholesterol levels 
compared to baseline and though there was an 
increase in W.somnifera 250 mg, it was not 
statistically significant. There was a significant 
change between the two active treatment 
groups for Total cholesterol (p<0.05) and HDL-
C (p<0.01), further the reduction in LDL-C, 
Triglycerides and VLDL-C levels between 
W.somnifera 250mg and 500mg was not 
statistically significant. The mean percent 
reduction in total cholesterol for W.somnifera 
250 mg and 500mg were 8.48 % and 14.8 % 
respectively compared to baseline. The mean 
percent reduction in LDL-C for W.somnifera 250 
mg and 500 mg were 10.74 % and 18.14 % 
respectively compared to baseline. The mean 
percentage reduction in triglycerides for 
W.somnifera 250 mg and 500mg were 11.8 % 
and 20.9% respectively compared to baseline.  
 The mean percent reductions in total 
cholesterol, LDL-C and triglycerides for 
W.somnifera 250 mg and 500mg were found to 
be significant compared to placebo. The mean 
percent reduction in VLDL-C for W.somnifera 
250 mg and 500mg were 3.05 % and 7.16 % 
respectively compared to baseline, but were not 
significant when compared to placebo. The 
mean percentage increase in HDL-C for 
W.somnifera 250 mg and 500 mg were 1.46 % 
and 15.00 % respectively compared to baseline. 
A significant increase in HDL-C was found only 
with W.somnifera 500 mg in comparison to 
placebo. However when compared between 
W.somnifera 250 mg and 500mg, statistical 
significance was achieved for increase in HDL-C 
and decrease in total cholesterol.  
DISCUSSION  
 In the present study, we evaluated the 
effect of W.somnifera 250 mg, W.somnifera 500 
mg and placebo on endothelial function in 
patients with diabetes. Both the active 
treatments have shown a beneficial effect on 
endothelial function, along with a significant 
improvement in biomarkers of oxidative stress 
(Nitric oxide, Glutathione, Malondialdehyde) 
and systemic inflammation (High sensitivity C 
Reactive Protein levels).  
Diabetes is associated with accelerated 
atherosclerosis and microvascular 
complications, which are the major causes of 
morbidity and mortality. Endothelial 
dysfunction is one of the early prognostic 
markers of atherosclerosis which eventually 
results in cardiovascular disease[17] and it has 
been reported that endothelial dysfunction 
occurs in patients with diabetes much earlier 
than the clinical manifestations of vascular 
complications of the disease[18]. In our earlier 
study, we reported the presence of endothelial 
dysfunction in diabetic patients assessed by 
salbutamol challenge test, indicating a decrease 
of 6% in RI, which is a marker of endothelial-
dependent vasodilatation[19]. In another study 
by us in diabetic patients, on treatment with 
polyherbal formulation, containing W.somnifera 
100mg as one of the constituent, there was a 
significant decrease in RI indicating 
improvement in endothelial function[20]. 
Similarly, in this study, treatment with 
W.somnifera 250mg and 500mg showed 
significant decrease in RI in type 2 diabetes 
mellitus compared to baseline and placebo. 
Endothelial dysfunction associated with 
diabetes has been attributed to a lack of bio 
available nitric oxide due to reduced ability to 
synthesize nitric oxide from L-arginine [21] 
Previous studies show that increased oxidative 
stress has the potential to impair NO 
bioavailability in several ways[22] in which 
superoxide anion may react with NO to form 
peroxynitrite and eliminate the biological 
activity of NO. Peroxynitrite is a highly reactive 
oxidant that may alter the catalytic activity of 
eNOS in endothelial cells and guanylyl cyclase 
in vascular smooth muscle cells. As a result, 
peroxynitrite reduces both the production of 
NO and the responsiveness of target tissues to 
NO[23]. In our study we observed a significant 
increase in NO levels in both active treatment 
groups suggesting a possible role in decreasing 
the endothelial dysfunction compared to 
baseline and placebo. Oxidative stress in 
diabetes mellitus owing to an increase in the 
production of oxygen free radicals, such as 
super oxide (O2•-), hydrogen peroxide (H2O2) 
 Int. J. Ayur. Pharma Research, 2014; 2(3): 22-32  ISSN: 2322 - 0910 
                                                                       Available online at : http://ijapr.in Page 28 
and hydroxide (OH•-) radicals and deficiency in 
antioxidant defense mechanisms. Increased 
non-enzymatic and auto oxidative glycosylation 
is one of the possible mechanisms that 
contribute to the formation of free radicals and 
free radical-induced lipid peroxidation in 
diabetes mellitus[24] Cellular enzymatic 
(superoxide dismutase) and non enzymatic 
(glutathione) antioxidants act as the primary 
line of defense to counteract the deleterious 
effects of these free radical species. Nakhjavani 
M et al. demonstrated a significant rise in serum 
MDA, oxidative stress marker in diabetics as 
compared to healthy controls[25]. In the present 
study we observed high MDA levels at baseline, 
which was significantly decreased on treatment 
with W.somnifera. A significant increase in 
glutathione levels with both active treatments 
was also recorded compared to baseline and 
placebo indicating improvement in antioxidant 
status. In another study by us with a polyherbal 
formulation (Cardipro®) with W.somnifera as 
one of the constituent, significant increase in 
GSH and a decrease in MDA levels were 
observed in patients with diabetes mellitus 
[19].Previous research suggests a positive 
relationship between components of the 
metabolic syndrome and markers of 
inflammation, such as C-reactive protein in the 
Atherosclerosis Risk in Communities study, in 
which there was a positive link found between 
systemic inflammation and the development of 
type 2 diabetes mellitus and its cardiovascular 
complications[26]. In a study, Tajiri et al. 
reported that increase in high-sensitivity C-
reactive protein a marker of systemic 
inflammation could be an important 
pathophysiological link between the metabolic 
syndrome and coronary artery disease[27]. In 
another study, FJ del Canizo Gomez et al. 
showed that increased serum hsCRP was one of 
the independent risk factors for the 
development of retinopathy in patients with 
type 2 diabetes mellitus[28]. In our study, 
treatment W.somnifera, showed a significant 
decrease in hsCRP compared to baseline and 
placebo.  
Diabetes being a metabolic disorder, 
lipid metabolism is also deranged leading to 
hyperlipidemias. Hypercholesterolemia along 
with hyperglycemia is a major risk factor for the 
development of atherosclerosis and is 
associated with coronary and peripheral 
vascular disease [29] Management of 
dyslipidemia, a well-recognized and modifiable 
risk factor, is a key element in the multifactorial 
approach to prevent CVD in individuals with 
type 2 diabetes. Andallu B et al. observed 
significant decrease in serum cholesterol, 
triglycerides, LDL (low density lipoproteins) 
and VLDL (very low density lipoproteins) 
cholesterol in six mild NIDDM subjects and six 
mild hypercholesterolemic subjects, treated 
with the powder of roots of W. somnifera for 30 
days indicating its potential as a natural source 
with hypolipidemic effects[30]. In another study 
by Ashwini kumar et al on 18 healthy 
volunteers for safety, tolerability and activity of 
W.somnifera, they observed a significant 
decrease in total cholesterol and decreasing 
trend was observed in triglycerides. However, 
no significant change in serum HDL, LDL, and 
VLDL cholesterol was seen.[31] In our study 
W.somnifera 500mg significantly decreased the 
total cholesterol, LDL Cholesterol, and 
triglyceride levels which are more likely to be 
raised in diabetic patients. 
CONCLUSION 
In the present study, treatment with 
highly standardized aqueous extract of 
W.somnifera 250mg and W.somnifera 500mg for 
12 weeks produced significant improvement in 
endothelial function in diabetic patients. A 
significant reduction in levels of biomarker for 
oxidative stress and systemic inflammation 
were observed suggesting an improvement in 
endothelial function. W.somnifera 500mg 
showed a significant reduction in lipid profile. 
All the treatments were well tolerated. It is 
suggested that W.somnifera could be further 
evaluated for its therapeutic role as an 
adjunctive in the management of diabetes 
mellitus associated with endothelial 
dysfunction. 
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PHOTOGRAPHS 
 
Figure 1: HPLC Chromatogram of SENSORIL
® 
(W.somnifera) with peaks for its active 
constituents, Withanolide glycosides and Withaferin-A.  
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Figure 2:  Absolute Change in RI after 12 weeks of Treatment 
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Figure 3: Mean Percent Change in NO, MDA Levels after 12 weeks of Treatment 
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Figure 4: Mean Percent Change in GSH, hsCRP Levels after 12 weeks of Treatment 
 
